Maria L. Ascierto, Ph.D. Saint John's Cancer Institute
Por um escritor misterioso
Descrição
Saint John's Cancer Institute's Director of Translational Immunology, Maria L. Ascierto, Ph.D. Contact Dr. Ascierto via email or phone number.
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect
Oncology - European Medical Journal
Upper Gastrointestinal & Endocrine Tumors - VHIO
Santa Monica Melanoma Symposium - A CME Event - April 30th, 2022 - Saint John's Cancer Institute
Previous Issues - JADPRO
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - ScienceDirect
FINAL PROGRAM - Society for Immunotherapy of Cancer
Michael A. Davies MD Anderson Cancer Center
Calaméo - Activity Report Iuct O 2019
Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial - Journal of Thoracic Oncology
Upper Gastrointestinal & Endocrine Tumors - VHIO
Funding the Best - Saint John's Health Center Foundation
de
por adulto (o preço varia de acordo com o tamanho do grupo)
